BridgeBio Presents Plans for Three Potential US Drug Launches by Mid-2027

Bitget2026/10/29 20:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BridgeBio has $1.5 billion in cash, cash equivalents and marketable securities to support three potential US launches by mid-2027.
Attruby generated $253.2 million in third-quarter 2026 US net product revenue, with potential peak sales exceeding $4 billion.
BBP-418's FDA decision date is November 27, 2026, with a US launch planned upon approval for LGMD2I/R9.
Infigratinib's FDA decision date is February 4, 2027, with a US launch planned upon approval for achondroplasia.
Encaleret's FDA decision date is May 8, 2027, with a US launch planned upon approval for autosomal dominant hypocalcemia type 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BridgeBio Presents Plans for Three Potential US Drug Launches by Mid-2027

You may also like

Crypto prices